Merck Serono Announces Collaboration with San Raffaele University & Research Hospital for Research in Neurodegenerative Diseases

Agreement for research in neurodegenerative diseases continues collaboration to develop pre-clinical and clinical research projects with a translational approach

30-Jul-2014 - Germany

Merck Serono, the biopharmaceutical division of Merck, and the Institute of Experimental Neurology (INSPE), part of San Raffaele University and Research Hospital in Milan, Italy, announced the continuation of a strategic alliance to develop pre-clinical and clinical research projects in the field of neurodegenerative diseases.

The research will focus on developing innovative therapies against serious and disabling neurological diseases affecting young adults in particular, such as multiple sclerosis. Established in 2004, the renewal of the partnership extends the agreement between the parties for two additional years.

"Merck Serono is pleased to continue the collaborative alliance with the San Raffaele Scientific Institute," said Harsukh Parmar, Senior Vice President, Global Head of Research & Early Development, Immunology & Neurology at Merck Serono. "Our translational approach to these disease states and combined commitment to expediting the discovery of new therapies aims to improve health outcomes for patients living with unmet medical needs."

San Raffaele University and Research Hospital will provide its know-how and its laboratories to develop new therapies and to evaluate the effectiveness of the molecules developed by Merck Serono.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances